A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 until the study ends.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rozpoznanie chłoniaka z komórek B - konkretnie chłoniaka pęcherzykowego lub dużokomórkowego
- •Ogólny stan zdrowia pozwalający na leczenie ambulatoryjne lub szpitalne
- •Przewidywana długość życia co najmniej 12 tygodni
- •Zmierzalne zmiany chorobowe widoczne w badaniach
- •Zdolność do uczestniczenia w wizytach klinicznych i badaniach krwi
- •Prawidłowe funkcjonowanie narządów wewnętrznych
✗ Disqualifies
- •Duża liczba białych krwinek w krwi wskazująca na zaangażowanie krwioobiegu
- •Zaangażowanie mózgu lub opon mózgowych
- •Historia chorób mózgu takich jak udar, epilepsja lub choroby neurodegeneracyjne
- •Niewyzdrowione skutki uboczne z poprzedniego leczenia powyżej stopnia 2
- •Przeszczep autologicznych komórek macierzystych w przeszłości
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 10, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (50)
City of Hope
Duarte, United States
University of Colorado Denver - School of Medicine - Anschutz Medical Campus
Aurora, United States
Colorado Blood Cancer Institute
Denver, United States
Yale University School of Medicine - Yale Cancer Center
New Haven, United States
The University of Chicago Medical Center (UCMC)
Chicago, United States
University of Iowa
Iowa City, United States
University of Kansas Cancer Center
Kansas City, United States
Massachusetts General Hospital
Boston, United States
Dana-Farber Cancer Institute
Boston, United States
University of Michigan Comprehensive Cancer Center
Ann Arbor, United States
Mayo Clinic - Rochester
Rochester, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, United States
New York University (NYU) Clinical Cancer Center
New York, United States
Weill Cornell Medicine
New York, United States
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, United States
Cleveland Clinic
Cleveland, United States
University of Pennsylvania Abramson Cancer Center
Philadelphia, United States
SCRI Oncology Partners
Nashville, United States
University of Texas Southwestern
Dallas, United States
MD Anderson Cancer Center
Houston, United States
Intermountain Healthcare
Salt Lake City, United States
Swedish Cancer Institute (SCI)
Seattle, United States
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, United States
The Alfred Hospital
Melbourne, VIC, Australia
Linear Clinical Research
Nedlands, Australia
Lady Davis Institute for Medical Research Jewish General Hospital
Montreal, Canada
University Health Network (UHN) - Princess Margaret Cancer Centre
Toronto, Canada
BC Cancer - Vancouver
Vancouver, Canada
Aarhus University Hospital
Aarhus, Denmark
Center for Cancer and Organ Diseases - Rigshospitalet
Copenhagen, Denmark
CHU de Lille - Hopital Claude Huriez
Lille, France
AP-HP Hopital Saint-Louis
Paris, France
Charite Universitaetsmedizin Berlin
Berlin, Germany
LMU Klinikum Muenchen-Campus Grosshadern
München, Germany
Universitaetsklinikum Muenster
Münster, Germany
IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola
Bologna, Italy
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
Naples, Italy
Istituto Clinico Humanitas
Rozzano, Italy
National Cancer Center Hospital East
Chiba, Japan
Okayama University Hospital
Okayama, Japan
The Cancer Institute Hospital of JFCR
Tokyo, Japan
Pratia MCM Krakow
Krakow, Poland
AIDPORT Sp. z o.o.
Skorzewo, Poland
Seoul National University Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Institut Catala d'Oncologia - L'Hospitalet
Barcelona, Spain
South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz
Madrid, Spain
Leeds Teaching Hospitals NHS Trust
Leeds, United Kingdom
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
Trial contact
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Physicians interested in becoming principal investigators please contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.